Phase I Trial of S-1153 in Patients With HIV Infection

Summary

To assess the toxicity profile and determine the maximum tolerated dose (MTD), if possible, of S-1153 administered orally 3 times daily for 14 days. To investigate the clinical pharmacokinetic parameters for S-1153. To assess anti-HIV activity associated with S-1153 administration through evaluation of CD4 and viral load measurements.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications